Simplex Trading’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-69,800
| Closed | -$5.03M | – | 9985 |
|
|
2025
Q4 | $5.03M | Buy |
69,800
+9,500
| +16% | +$614K | ﹤0.01% | 1257 |
|
|
2025
Q3 | $2.63M | Buy |
60,300
+58,700
| +3,669% | +$2.37M | ﹤0.01% | 2047 |
|
|
2025
Q2 | $45K | Buy |
1,600
+800
| +100% | +$23.8K | ﹤0.01% | 6029 |
|
|
2025
Q1 | $23K | Buy |
800
+200
| +33% | +$6.23K | ﹤0.01% | 6476 |
|
|
2024
Q4 | $17K | Sell |
600
-1,400
| -70% | -$58.5K | ﹤0.01% | 6822 |
|
|
2024
Q3 | $91K | Sell |
2,000
-50,300
| -96% | -$2.18M | ﹤0.01% | 5325 |
|
|
2024
Q2 | $2.14M | Buy |
52,300
+39,300
| +302% | +$1.13M | ﹤0.01% | 2137 |
|
|
2024
Q1 | $331K | Buy |
13,000
+10,100
| +348% | +$158K | ﹤0.01% | 4278 |
|
|
2023
Q4 | $26K | Buy |
2,900
+2,400
| +480% | +$16K | ﹤0.01% | 6709 |
|
|
2023
Q3 | $3K | Sell |
500
-3,100
| -86% | -$26.7K | ﹤0.01% | 7946 |
|
|
2023
Q2 | $39K | Buy |
3,600
+100
| +3% | +$1.25K | ﹤0.01% | 6079 |
|
|
2023
Q1 | $53K | Sell |
3,500
-46,400
| -93% | -$1.02M | ﹤0.01% | 5856 |
|
|
2022
Q4 | $1.11M | Buy |
49,900
+48,400
| +3,227% | +$722K | ﹤0.01% | 2364 |
|
|
2022
Q3 | $24K | Buy |
1,500
+1,300
| +650% | +$24.9K | ﹤0.01% | 7334 |
|
|
2022
Q2 | $2K | Sell |
200
-100
| -33% | -$1.49K | ﹤0.01% | 9411 |
|
|
2022
Q1 | $5K | Hold |
300
| – | – | ﹤0.01% | 9442 |
|
|
2021
Q4 | $7K | Buy |
+300
| New | +$7.17K | ﹤0.01% | 9335 |
|
Other funds holding RNAM
Simplex Trading's RNAM Position: Q1 2026 in Review
Simplex Trading sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 38,607 shares — an estimated $2.78M sold.
Simplex Trading first reported a position in RNAM in Q4 2021 and held it in 10 quarters. The position peaked at $2.78M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Simplex Trading reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Simplex Trading sold 38,607 Avidity Biosciences shares in Q1 2026, an estimated $2.78M.
- Simplex Trading first reported a position in Avidity Biosciences in Q4 2021 and held it in 10 quarters.
- Simplex Trading's Avidity Biosciences position peaked at $2.78M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.